Skip to main content
Fig. 2 | Critical Care

Fig. 2

From: Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial

Fig. 2

Primary endpoint: PaO2/FiO2 values and their changes between days 0 and 7. A Baseline (D0) and D7 PaO2/FiO2 ratios were similar for the two groups. Box plots of PaO2/FiO2 ratios: internal horizontal lines are the medians; lower and upper box limits are the 25th–75th interquartile range, respectively; and vertical bars represent the 10th and 90th percentiles. B PaO2/FiO2 ratios increased significantly from D0 to D7 in the UC-MSC group (respectively, 156.2 ± 68.2 vs 188.3 ± 74.2; Wilcoxon signed-rank exact test). The placebo group’s PaO2/FiO2 ratios on D0 and D7 were comparable (respectively, 171.2 ± 72.9 vs 169.8 ± 85.6, Wilcoxon signed-rank exact test). UC-MSCs group in red; placebo group in blue. D day. PaO2/FiO2 ratio of partial pressure of oxygen to fractional inspired oxygen. UC-MSCs umbilical cord-derived mesenchymal stromal cells

Back to article page